BREO ELLIPTA®

Drug Information Related Patent
Hold Company
GLAXOSMITHKLINE
Learn More
Dosage and Administration
POWDER;INHALATION
Specification
0.1MG/INH;EQ 0.025MG BASE/INH
0.2MG/INH;EQ 0.025MG BASE/INH
0.05MG/INH;EQ 0.025MG BASE/INH
Indication
BREO ELLIPTA® is suitable for the maintenance treatment of chronic obstructive pulmonary disease and the maintenance treatment of asthma.
Use
Instructions for Use
API
FLUTICASONE FUROATE
VILANTEROL TRIFENATATE
API Structure
We Supply
FLUTICASONE FUROATE
Note:

In-house Standard
Facility GMP
USMF/CDE/ASMF/CEP

VILANTEROL TRIFENATATE
Note:

Commercial

null
Note:

null

Drug Patent
Patent NoExpiration Date
111167212029/2/26
11116721*PED2029/8/26
74393932025/5/21
7439393*PED2025/11/21
81131992027/10/23
8113199*PED2028/4/23
81619682028/2/5
8161968*PED2028/8/5
85113042027/6/14
8511304*PED2027/12/14
85342812030/3/8
8534281*PED2030/9/8
87462422030/10/11
8746242*PED2031/4/11
93333102027/10/2
9333310*PED2028/4/2
API Patent
Patent NoExpiration Date
74393932025/5/21
7439393*PED2025/11/21
HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen-ING. All Rights Reserved.
dcat
Member of
dcat
Top